Free Trial

IDEXX Laboratories (IDXX) Competitors

IDEXX Laboratories logo
$533.76 +0.40 (+0.07%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDXX vs. IQV, MCO, NVST, ZTS, BSX, SYK, MDT, BDX, EW, and RMD

Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include IQVIA (IQV), Moody's (MCO), Envista (NVST), Zoetis (ZTS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and ResMed (RMD).

IDEXX Laboratories vs. Its Competitors

IQVIA (NYSE:IQV) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, IDEXX Laboratories had 9 more articles in the media than IQVIA. MarketBeat recorded 32 mentions for IDEXX Laboratories and 23 mentions for IQVIA. IDEXX Laboratories' average media sentiment score of 1.09 beat IQVIA's score of 0.98 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IQVIA
13 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
21 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IQVIA currently has a consensus target price of $222.45, indicating a potential upside of 38.49%. IDEXX Laboratories has a consensus target price of $558.11, indicating a potential upside of 4.56%. Given IQVIA's higher possible upside, analysts clearly believe IQVIA is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA
0 Sell rating(s)
7 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.75
IDEXX Laboratories
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.80

IQVIA has higher revenue and earnings than IDEXX Laboratories. IQVIA is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$15.41B1.80$1.37B$7.3421.88
IDEXX Laboratories$3.93B10.92$887.87M$10.8249.33

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.6% of IQVIA shares are owned by company insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IDEXX Laboratories has a net margin of 22.76% compared to IQVIA's net margin of 8.61%. IDEXX Laboratories' return on equity of 57.35% beat IQVIA's return on equity.

Company Net Margins Return on Equity Return on Assets
IQVIA8.61% 29.16% 6.96%
IDEXX Laboratories 22.76%57.35%26.97%

IQVIA has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Summary

IDEXX Laboratories beats IQVIA on 10 of the 16 factors compared between the two stocks.

Get IDEXX Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDXX vs. The Competition

MetricIDEXX LaboratoriesMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$42.96B$6.71B$5.54B$9.13B
Dividend YieldN/A1.28%5.06%4.01%
P/E Ratio49.3726.4628.2819.58
Price / Sales10.9262.34373.3579.96
Price / Cash42.9120.6824.7227.50
Price / Book27.404.718.265.55
Net Income$887.87M$174.76M$3.19B$252.28M
7 Day Performance-2.16%1.45%5.27%2.99%
1 Month Performance2.12%2.12%9.19%11.65%
1 Year Performance8.33%6.84%30.12%17.15%

IDEXX Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDXX
IDEXX Laboratories
3.554 of 5 stars
$533.77
+0.1%
$558.11
+4.6%
+8.2%$42.96B$3.93B49.3711,000Positive News
Analyst Upgrade
IQV
IQVIA
4.9232 of 5 stars
$162.57
-1.0%
$226.32
+39.2%
-27.4%$28.12B$15.41B22.1588,000Analyst Revision
MCO
Moody's
4.7153 of 5 stars
$502.51
-0.5%
$520.73
+3.6%
+12.0%$90.40B$7.09B43.3915,838Positive News
NVST
Envista
3.2638 of 5 stars
$19.66
-3.6%
$20.23
+2.9%
+25.9%$3.33B$2.51B-3.0112,300
ZTS
Zoetis
4.9187 of 5 stars
$156.98
-1.4%
$212.13
+35.1%
-13.5%$69.89B$9.26B28.1813,800Positive News
BSX
Boston Scientific
4.6336 of 5 stars
$103.75
-0.5%
$116.09
+11.9%
+32.8%$153.49B$16.75B75.7353,000
SYK
Stryker
4.7959 of 5 stars
$392.26
-0.8%
$427.30
+8.9%
+14.7%$149.72B$22.60B53.0153,000Positive News
MDT
Medtronic
4.5876 of 5 stars
$87.73
-0.7%
$97.87
+11.6%
+15.5%$112.52B$33.54B24.2395,000Positive News
Analyst Forecast
BDX
Becton, Dickinson and Company
4.9503 of 5 stars
$172.92
-1.8%
$219.22
+26.8%
-23.2%$49.56B$20.18B33.0074,000Positive News
EW
Edwards Lifesciences
4.3701 of 5 stars
$76.64
-0.2%
$80.20
+4.6%
-14.2%$44.96B$5.44B10.9515,800Positive News
RMD
ResMed
4.161 of 5 stars
$256.16
-0.3%
$259.33
+1.2%
+24.1%$37.56B$4.69B28.759,980Positive News

Related Companies and Tools


This page (NASDAQ:IDXX) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners